Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA
Launched by DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL · Jan 6, 2020
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Post-menopausal women with subjective symptomatology of vulvovaginal atrophy
- • Signed written informed consent before participation in the trial
- Exclusion Criteria:
- • Known hypersensitivity against any of the ingredients of the investigational product
- • Systemic hormonal replacement therapy, or phytohormonal therapy or use of SERMs within 3 months before and / or during the conduct of the trial
- • Local hormonal therapy (vagina/vulva) within 3 months before the trial
- • If in the opinion of the investigator the patient should not participate in the study for any reason
About Dr. August Wolff Gmbh & Co. Kg Arzneimittel
Dr. August Wolff GmbH & Co. KG Arzneimittel is a distinguished pharmaceutical company based in Germany, specializing in the development and manufacturing of innovative medicinal products with a focus on dermatological and gynecological therapies. With a commitment to quality and efficacy, the company leverages advanced research and development methodologies to enhance patient care. Dr. August Wolff is dedicated to improving healthcare outcomes through clinical trials that explore new treatment options, ensuring compliance with rigorous regulatory standards while fostering collaboration within the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Schenefeld, , Germany
Patients applied
Trial Officials
Kirstin Deuble-Bente, MD
Principal Investigator
proDERM Institute for Applied Dermatological Research, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials